Scholar Rock (SRRK) CMO awarded 34,482 time-vested RSUs

Rhea-AI Filing Summary

Marantz Jing L. reported acquisition or exercise transactions in this Form 4 filing.

Scholar Rock Holding Corp’s Chief Medical Officer, Jing L. Marantz, received a grant of 34,482 restricted stock units (RSUs) of common stock on February 9, 2026. The award was reported at a price of $0.00 per share as a compensation grant.

Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments over four years, with the first installment scheduled for January 15, 2027, as long as Dr. Marantz continues a service relationship with the company on each vesting date. After this grant, she directly holds 130,169 common shares and RSUs in total, consisting of 24,974 common shares and 105,195 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marantz Jing L.

(Last) (First) (Middle)

301 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Scholar Rock Holding Corp [ SRRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		34,482(1)	A	$0.00	130,169(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

2. Consists of 24,974 shares of common stock and 105,195 RSUs.

	/s/ Junlin Ho, Attorney-in-Fact for Jing Marantz	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Scholar Rock (SRRK) report for Jing L. Marantz?

Scholar Rock reported a compensation grant of 34,482 restricted stock units (RSUs) of common stock to Chief Medical Officer Jing L. Marantz. These RSUs were awarded at a stated price of $0.00 per share and are subject to multi-year time-based vesting conditions.

When do the new RSUs granted to the Scholar Rock (SRRK) CMO start vesting?

The RSUs begin vesting on January 15, 2027. The 34,482 restricted stock units vest in four equal annual installments over four years, with one installment vesting each year, provided Jing L. Marantz maintains a service relationship with Scholar Rock on each applicable vesting date.

How many Scholar Rock (SRRK) shares and RSUs does Jing L. Marantz hold after this Form 4?

After the reported grant, Jing L. Marantz beneficially owns 130,169 units, consisting of 24,974 shares of common stock and 105,195 restricted stock units. This total reflects her direct ownership following the grant of 34,482 additional RSUs reported in the Form 4 filing.

What type of transaction is reported in this Scholar Rock (SRRK) Form 4?

The filing reports an acquisition through a grant/award of non-derivative securities. Specifically, it shows a grant of 34,482 restricted stock units (RSUs) of common stock to the Chief Medical Officer, coded as an acquisition (transaction code A) rather than an open-market purchase.

What are the vesting conditions for the new Scholar Rock (SRRK) RSU grant?

The RSUs are subject to time-based vesting. The 34,482 RSUs vest in four annual installments over four years, starting January 15, 2027. Each subsequent annual installment vests only if Jing L. Marantz continues her service relationship with Scholar Rock on the relevant vesting date.